The discovery and preclinical development of ASG-5ME, an antibody-drug conjugate targeting SLC44A4-positive epithelial tumors including pancreatic and prostate cancer

Molecular Cancer Therapeutics

Volumn 15, Issue 11, 2016, Pages 2679-2687

  Mattie, Michael ^a   Raitano, Arthur ^a   Morrison, Kendall ^a   Morrison, Karen ^a   An, Zili ^a   Capo, Linnette ^a   Verlinsky, Alla ^a   Leavitt, Monica ^a   Ou, Jimmy ^a   Nadell, Rossana ^a   Aviña, Hector ^a   Guevara, Claudia ^a   Malik, Faisal ^a   Moser, Ruth ^b   Duniho, Steven ^b   Coleman, Jeffrey ^a   Li, Ying ^a   Pereira, Daniel S ^a   Doñate, Fernando ^a   Joseph, Ingrid B J ^a   Challita Eid, Pia ^a   Benjamin, Dennis ^b   Stover, David R ^a   more..

^a ASTELLAS PHARMA INC   (Japan)

^b SEATTLE GENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASG 5ME; MONOCLONAL ANTIBODY; PACLITAXEL; RECEPTOR; SOLUTE CARRIER RECEPTOR SLC44A4; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; ASG-5ME; CARRIER PROTEIN; CHOLINE TRANSPORTER-LIKE PROTEIN 4, HUMAN; OLIGOPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHO CELL LINE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE DRUG DOSE; TUMOR XENOGRAFT; ANIMAL; CARCINOMA; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; PRECLINICAL STUDY; PROSTATIC NEOPLASMS; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION PROFILING; HUMANS; IMMUNOCONJUGATES; MALE; MEMBRANE TRANSPORT PROTEINS; MICE; MOLECULAR TARGETED THERAPY; OLIGOPEPTIDES; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84995528432     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0225     Document Type: Article

References (17)

1. Inazu M, Takeda H, Matsumiya T. Molecular and functional characterization of an Na+-independent choline transporter in rat astrocytes. J Neurochem 2005; 94: 1427-37.
2. Traiffort E, Ruat M, O'Regan S, Meunier FM. Molecular characterization of the family of choline transporter-like proteins and their splice variants. J Neurochem 2005; 92: 1116-25.
3. Uchida Y, Inazu M, Takeda H, Yamada T, Tajima H, Matsumiya T. Expression and functional characterization of choline transporter in human keratinocytes. J Pharmacol Sci 2009; 109: 102-9.
4. Kouji H, Inazu M, Yamada T, Tajima H, Aoki T, Matsumiya T. Molecular and functional characterization of choline transporter in human colon carcinoma HT-29 cells. Arch Biochem Biophys 2009; 483: 90-8.
5. Yamada T, Inazu M, Tajima H, Matsumiya T. Functional expression of choline transporter-like protein 1 (CTL1) in human neuroblastoma cells and its link to acetylcholine synthesis. Neurochem Int 2010; 58: 354-65.
6. Nakamura T, Fujiwara R, Ishiguro N, Oyabu M, Nakanishi T, Shirasaka Y, et al. Involvement of choline transporter-like proteins, CTL1 and CTL2, in glucocorticoid-induced acceleration of phosphatidylcholine synthesis via increased choline uptake. Biol Pharm Bull 2010; 33: 691-6.
7. Kommareddi PK, Nair TS, Thang LV, Galano MM, Babu E, Ganapathy V, et al. Isoforms, expression, glycosylation, and tissue distribution of CTL2/SLC44A2. Protein J 2010; 29: 417-26.
8. Song P, Rekow SS, Singleton CA, Sekhon HS, Dissen GA, Zhou M, et al. Choline transporter-like protein 4 (CTL4) links to non-neuronal acetylcholine synthesis. J Neurochem 2013; 126: 451-61.
9. Nabokina SM, Inoue K, Subramanian VS, Valle JE, Yuasa H, Said HM. Molecular identification and functional characterization of the human colonic thiamine pyrophosphate transporter. J Biol Chem 2014; 289: 4405-16.
10. Muller AJ, Young JC, Pendergast AM, Pondel M, Landau NR, Littman DR, et al. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive leukemias. Mol Cell Biol 1991; 4: 1785-92.
11. Green L.Antibody engineering via genetic engineering of the mouse: XenoMouse strains are vehicles for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 1999; 231: 11-23.
12. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003; 21: 778-84.
13. Berdanier CD. Advanced nutrition micronutrients. Boca Raton, FL: CRC Press; 1998.
14. Bettendorff L, Wins P. Thiamin diphosphate in biological chemistry. New aspects of thiamin metabolism, especially triphosphate derivatives acting other than as cofactors. FEBS J 2009; 276: 2917-25.
15. Gumbiner B. The structure, biochemistry, and assembly of epithelial TJs. Am J Physiol 1987; 253: C749-C758.
16. Brandtzaeg P. Mucosal and glandular distribution of immunoglobulin components: Differential localization of free and bound SC in secretory epithelial cells. J Immunol 1974; 112: 1553-9.
17. Yoshida M, Claypool SM, Wagner JS, Mizoguchi E, Mizoguchi A, Roopenian DC, et al. Human neonatal Fc receptormediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 2004; 20: 769-83.